Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Apr
01
Today In Oncology
Early Results From a Trial of Active Surveillance for Low-Risk DCIS Are Reassuring Say Researchers
AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC
Machine-Learning Model for HCC Risk Prediction May Outperform Current Methods
Nivolumab With or Without Ipilimumab in Platinum-Refractory Advanced Neuroendocrine Carcinoma
Molecular Test Doubles Detection of Bile Duct Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo